Status:
NOT_YET_RECRUITING
Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
Stanford University
Conditions:
Brugada Syndrome (BrS)
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to learn if Empagliflozin works to treat Brugada syndrome patients by affecting their electrocardiographic (ECG) patterns, and to evaluate its safety. The main ques...
Detailed Description
Inclusion Criteria 1. Patients diagnosed with Brugada syndrome and aged 18-99 years with spontaneous type 1 ECG, normal structural heart and patent coronary artery 2. Obtain written informed consent ...
Eligibility Criteria
Inclusion
- Patients diagnosed with Brugada syndrome and aged 18-99 years with spontaneous type 1 ECG, normal structural heart and patent coronary artery
- Obtain written informed consent for participation in the clinical trial
Exclusion
- Individuals with type 1 ECG pattern only observed with fever-induced or drug-induced were excluded from this exploratory study.
- Current or prior use of an SGLT2 inhibitor within 12 weeks before screening or randomization
- Known allergy or hypersensitivity to any SGLT2 inhibitor
- History of ketoacidosis
- Symptomatic hypotension or systolic blood pressure \<90 mmHg or \>180 mmHg
- Heart failure
- Acute myocardial infarction
- ALT or AST \>3× ULN at screening
- Impaired renal function (eGFR \<20 mL/min/1.73 m² \[MDRD\]), requiring dialysis, or functioning kidney transplant at screening
- Pregnancy, nursing, or planning pregnancy during the trial
- Enrollment in another investigational drug or device study or completion of such a study within the last 30 days
- Known poor adherence to clinic visits or prescribed medications
- Medical conditions that may limit trial participation, including severe respiratory disease, history of cancer with metastasis in the past four years (excluding non-melanoma skin cancer), or recent alcohol/substance misuse
Key Trial Info
Start Date :
September 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 21 2027
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT07146880
Start Date
September 15 2025
End Date
September 21 2027
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, Taiwan, 100